Physician profile
Gail Edna Kwarciany
NPI 1649414731
$3,698.04
in general payments reported to CMS, 2019-2025
22 companies · $688 in 2025
The $688 reported for 2025 was more than what 93% of Oncology (Registered Nurse) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,171 · 2022: $862 · 2023: $753 · 2024: $224 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.02 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $654.67 | 2021-2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $568.57 | 2022-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $347.08 | 2022-2023 | Keytruda |
| Gilead Sciences, INC. | $262.75 | 2021-2023 | Epclusa, Trodelvy |
| Puma Biotechnology, INC. | $225.52 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $198.66 | 2023-2025 | Libtayo |
| Seagen INC. | $196.84 | 2021-2023 | |
| Amgen INC. | $121.84 | 2022 | |
| Beigene USA, INC. | $121.48 | 2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $121.35 | 2025 | |
| Taiho Oncology, INC. | $102.60 | 2024 | |
| Genzyme Corporation | $100.39 | 2021 | |
| Springworks Therapeutics, INC. | $100.00 | 2025 | Ogsiveo |
| Edwards Lifesciences Corporation | $89.89 | 2022 | |
| Stemline Therapeutics INC. | $89.78 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $87.51 | 2021 | |
| Mylan Specialty L.P. | $85.09 | 2023 | Yupelri |
| Eisai INC. | $81.24 | 2021 | |
| Astellas Pharma US INC | $66.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $42.81 | 2025 | |
| Recordati_rare_diseases_inc. | $18.23 | 2025 | Sylvant |
| Btg International INC. | $14.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Kwarciany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.